433226-06-3

Basic information

• Product Name: ETHYL 2-AMINO-5-BROMONICOTINATE
• Synonyms: ETHYL 2-AMINO-5-BROMONICOTINATE;Ethyl 2-amino-5-bromopyridine-3-carboxylate;Ethyl 2-amino-5-bromopyridine-3-carboxylate, 2-Amino-5-bromo-3-(ethoxycarbonyl)pyridine;3-Pyridinecarboxylic acid, 2-aMino-5-broMo-, ethyl ester
• CAS NO: 433226-06-3
• Molecular Formula: C8H9BrN2O2
• Molecular Weight: 245.07
• Mol File: 433226-06-3.mol
• Article Data: 14

Chemical Properties

• Melting Point: 139-141°
• Boiling Point: 290.6±35.0 °C(Predicted)
• Appearance: /
• Density: 1.575±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 2.59±0.49(Predicted)
• CAS DataBase Reference: ETHYL 2-AMINO-5-BROMONICOTINATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 2-AMINO-5-BROMONICOTINATE(433226-06-3)
• EPA Substance Registry System: ETHYL 2-AMINO-5-BROMONICOTINATE(433226-06-3)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 433226-06-3(Hazardous Substances Data)

Usage

General Description

ETHYL 2-AMINO-5-BROMONICOTINATE is a chemical compound with the molecular formula C8H8BrN3O2. It is a derivative of nicotinic acid and contains an ethyl ester group, an amino group, and a bromine atom attached to the aromatic ring. ETHYL 2-AMINO-5-BROMONICOTINATE has been studied for its potential use in medicinal and pharmaceutical applications, particularly in the development of new drugs and pharmaceutical products. Its properties and potential biological activities make it a subject of interest for further research in the field of organic chemistry and pharmaceutical sciences.

Upstream product

• 13362-26-0 2-aminopyridine-3-carboxylic acid ethyl ester 
• 5345-47-1 2-aminopyridin-3-carboxylic acid 
• 114078-88-5 5-bromo-1,2,3-triazine 
• 105-56-6 ethyl 2-cyanoacetate 
• 14667-47-1 methyl 2-aminonicotinate 

Downstream Products

• 1801262-20-3 6-bromo-[1,2,4]triazolo[1,5-a]pyridine-8-carboxylic acid methyl ester 
• 155690-79-2 6-bromo-3H,4H-pyrido[2,3-d]pyrimidin-4-one 
• 1215787-31-7 6-bromo-4-chloropyrido[2,3-d]pyrimidine 

Relevant articles and documents

Synthesis of 5H-pyrido[3,2-b]pyrrolizin-5-one tripentone analogs with antitumor activity

Pyrrolizinones represent an interesting class of compounds with varied degrees of structural complexity and pharmacological activity. Among these, 9H-pyrido[2,3-b]pyrrolizin-9-one, tripentone analogs, recently reported by us, showed significant antiproliferative activity against human tumor cell lines, inducing apoptosis and not affecting viability of Caco-2 differentiated in normal intestinal-like cells. Considering their interesting biological activity, their 5H-pyrido[3,2-b]pyrrolizin-5-one analogs were efficiently synthesized in good to excellent yields (61–91%). All tripentone derivatives were tested to assess their cytotoxicity against two human tumor cell lines, HCT-116 (human colorectal carcinoma) and MCF-7 (human breast cancer). The most active derivatives, with IC50 ranging from 0.11 to 16.11 μM, did not affect viability of Caco-2 differentiated in normal intestinal-like cells, suggesting tumor cells as the main target of their cytotoxic action. The same compounds, further investigated, showed that they did not exert necrotic effects, while induced a clear shift of viable cells towards early apoptosis confining the cells in the mitotic phases.

SYNTHESIS, X-RAY STRUCTURE ANALYSIS, AND VIBRATIONAL SPECTRAL STUDIES OF 1-(3-((6-BROMOPYRIDO[2,3-d]PYRIMIDIN-4-YL) OXY)PHENYL)-3-CYCLOPENTYLUREA

Abstract: A new pyrido[2,3-d]pyrimidine derivative 1-(3-((6-bromopyrido[2,3-d]pyrimidin-4-yl)oxy)phenyl)-3-cyclopentylurea is designed and synthesized. The final structure is characterized by 1H, 13C, and 2D NMR, MS, FTIR. In addition, the crystal structure of the title compound is determined by X-ray diffraction. With the 6-311G(2d,p) basis set, the molecule is further explored using density functional theory (DFT) by the B3LYP method. The final results show that the DFT optimized structure of the title molecule is consistent with the crystal structure determined by X-ray diffraction. The Hirshfeld surface analysis and the 2D fingerprint plot are given to support the quantitative analysis of intermolecular interactions and contacts generated by supramolecular accumulation in crystals. The interactions of the title molecule are analyzed by the natural bond orbital analysis. Finally, the molecular electrostatic potential and frontier molecular orbitals are further investigated using DFT. [Figure not available: see fulltext.]

Pyrido[2,3-d]pyrimidine compound as well as preparation method and application thereof

The present invention discloses a pyrido[2,3-d]pyrimidine compound represented by a general formula I or a pharmaceutically acceptable salt thereof. The general formula I is shown as the specification, wherein R1 is selected from one of an alkylamine group of C1-C6, an alicyclic amine group of C1-C6, a heterocyclic amine group of C1-C6, and an aromatic amine group of C6-C8, and X represents a hydrogen atom or a halogen atom. According to the invention, in-vitro cell activity tests prove that the compound provided by the invention has antitumor activity and can be used for preparing medicines for treating and/or preventing various cancers caused by BRaf kinase mutation, such as melanoma, thyroid cancer, breast cancer, liver cancer, kidney cancer, colorectal cancer, pancreatic cancer, ovarian cancer, etc.